Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (June 2011)

22 slides from Zydus Lifesciences's investor presentation, June 2011

  1. Slide 1: Cadila Healthcare Ltd. Investor Presentation

    Cadila Healthcare Ltd. Investor Presentation June 2011 BSE : 532321 NSE : CADILAHC 1

  2. Slide 2: Our Vision

    Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline; Stepping beyond the billion, we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2

  3. Slide 3: A Snapshot

    A Snapshot ƒ One of the largest company in the Indian formulations market worth over Rs. 480 bn (Source : ORG IMS MAT Mar-11) ƒ Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa and Middle East regions ƒ International sales in generic markets contribute to >42% of revenues, with >

  4. Slide 4: Well integrated company and expanding Globally

    Well integrated company and expanding Globally Revenue break up (%) by segment (FY 10-11) APIs, 9% India ▲8% Formulations , 38% ▲19% Indian finished International dosage finished dosage formulations formulations India Exports Consumer, Formulations India 7% , 43%▲37% Others, 3% ▲16% ▲25% High end AP

  5. Slide 5: State of the art facilities and infrastructure (1/2)

    State of the art facilities and infrastructure (1/2) Formulations Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Moraiya (USFDA Approved) Sikkim Baddi Finished Dosage Form, Finished Dosage Form, Goa Agiolax (for Madaus), Goa Brazil Cytotoxic Injectables for Cytotoxic Injectable Tr

  6. Slide 6: State of the art facilities and infrastructure (2/2)

    State of the art facilities and infrastructure (2/2) APIs and Fine Chemicals R&D API, Ankleshwar API, Dabhasa Zydus Research Center, (USFDA Approved) (USFDA approved) Moraiya Fine Chemicals, Moraiya Biologics Active Substances, Pharmaceutical Technology (USFDA Approved) Changodar Center, Moraiya Pan

  7. Slide 7: Financial highlights

    Financial highlights ▲26% ▲27% ▲26% ▲33% ▲40% ▲40% ▲57% ▲57% # Net Profit and EPS exclude Exceptional Items. 7

  8. Slide 8: One of the largest in Indian Pharma market with ~Rs 18 bn sales

    One of the largest in Indian Pharma market with ~ Rs 18 bn sales ƒ Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory (participated market segments) Therapeutic Area-wise Sales Break-up of Branded Formulations (FY 10-11) ƒ 17 brands amongst country’s top 300 brands ƒ New

  9. Slide 9: International formulations: two-fold focus

    International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets (~32% of global sales) (~11% of global sales) 9 US - Zydus Pharmaceuticals USA Inc. 9 Brazil – 9 Europe • Branded - Quimica e Pharmaceutica Nikkho Do Brazil Ltda. • France - Zydus Fra

  10. Slide 10: Among the top 20 and one of the fastest growing generic companies in US

    Among the top 20 and one of the fastest growing generic companies in US ƒ Started operations in 2005 and adopted a “Customer Centric Model” ƒ Ranked 12th amongst the top US generic ▲44% companies based on scripts (Source : IMS) ▲69% ƒ Among the top three players in the market for nine out of the top

  11. Slide 11: 9th largest generic company in France; among top 20 in Spain

    9th largest generic company in France; among top 20 generic companies in Spain Among top 10 in Euro 3 bn French generics market with over 2.5% market share ƒ Launched >200 presentations (>90 molecules) in France so far ƒ Focusing on expanding market coverage thru new product launches incl. Day 1 opp

  12. Slide 12: Strategies for Japan: World's 2nd largest pharma market

    Strategies for Japan : World’s 2nd largest pharma market ƒ Generic market valued at >$ 3.5 bn, growing at over 10%, with low generic penetration of ~7% in value terms, 22% in volume terms (Source : IGPA) ƒ Acquired Nippon Universal Pharma. Ltd. (now Zydus Pharma Japan - ZPJ), with a marketing set-up

  13. Slide 13: Strategies for $13bn Brazilian pharma market

    Strategies for $ 13bn Brazilian pharma market ƒ Set up Zydus Healthcare Brazil Ltda. (100% Sales in Brazil (Rs. Mio.) subsidiary) to enter generics market in 2005-06 2,250 ▲24% ƒ Filed 64 dossiers so far for generic and 1,628 1,818 branded products from India, of which 23 ▲12% have been approved. ƒ

  14. Slide 14: Achievements in the fast growing emerging markets

    Achievements in the fast growing emerging markets ƒ Operations in ~20 semi / non regulated emerging markets of Asia Pacific, Africa and Middle East regions ƒ Focusing on rapidly growing markets of South Africa, Taiwan and Philippines ƒ No.1 Indian company in Uganda and Sudan and amongst top 3 Indian

  15. Slide 15: Strong brand equity in highly potential consumer wellness segment in India

    Strong brand equity in highly potential consumer wellness segment in India ƒ Zydus Wellness Ltd. – spearheading operations in Sales - Zydus Wellness (Rs. Mio.) consumer wellness segment 3,355 ▲25% ƒ Strong presence in niche categories 2,675 1,947 ▲37% ƒ India’s largest selling sugar substitute with

  16. Slide 16: Unlocking value through win-win alliances

    Unlocking value through win-win alliances ƒ Zydus Nycomed JV – most successful contract manufacturing JV in India ƒ State-of-the-art mfg. facility for Pantoprazole key intermediates ƒ Commissioned the expanded facility to manufacture complex high-end APIs for Nycomed ƒ Zydus Hospira - JV for oncolog

  17. Slide 17: Ongoing Investment in Newer Portfolios Worth over $180 bn

    Ongoing Investment in Newer Portfolios Worth over $ 180 bn Long term Novel discovery products Mid term from Zydus NME pipeline Biogenerics : 40 bn Near term Transdermal : 10 bn Vaccine : 22 bn Pulmonary : 20 bn Topical : 16 bn Transdermal : 10 bn Current Business Injectables : 17 bn Oncology : 55 bn

  18. Slide 18: A scientific talent pool of >1050 and investing over 6% of turnover on research

    A scientific talent pool of >1050 and investing over 6% of the turnover on research Talent Pool of >1050 Scientists Zydus Research Centre (ZRC) – Ahmedabad NME & Drug Discovery ƒ Focus on NME Research, 425 scientists Biologicals & NDDS Pharmaceutical Technology Centre – Ahmedabad and Mumbai Generics

  19. Slide 19: Dedicated facility for NME research: Zydus Research Centre

    Dedicated facility for NME research : Zydus Research Centre ƒ Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation ƒ Facility for target identification to pre- clinical research / early clinical development ƒ Signed a new drug discovery and development pact with Eli Lilly and Co., focused o

  20. Slide 20: Biosimilars and Vaccines – The Next Big Opportunity

    Biosimilars and Vaccines – The Next Big Opportunity Biosimilars : ƒ Strong pipeline: 17 biosimilars and 2 novel products ƒ Strong IP position either through own patent or non-infringing processes ƒ 120 experienced scientists dedicated to Biosimilars programme ƒ End to end product development and mfg

  21. Slide 21: Key Financial Numbers – FY 2010-11

    Key Financial Numbers – FY 2010-11 Rs. Mio. Growth Consolidated Profitability 2010-11 2009-10 y-y% Domestic Sales 22,324 18,724 19.2% Exports Sales 22,887 17,418 31.4% Total Gross Sales 45,211 36,142 25.1% Total Income from Operations 46,302 36,868 25.6% EBIDT 10,262 8,086 26.9% EBIDT % to Total Inc

  22. Slide 22: Safe Harbour Statement

    Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims a

Cadila Healthcare — Investor Presentation (June 2011) on 6ix